OOIR: Observatory of International Research

Papers

(The median citation count of Clinical Infectious Diseases is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
In the Literature	414
Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club	378
Reply to Focosi et al	375
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial	374
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With an Indoor Music Event That Required Proof of Full Vaccination Against Coronavirus Disease 2019 (COVID-19) Prio	371
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms	367
Withdrawn as duplicate: Cover image/text	352
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary	348
Reply to van Crevel, et al	268
COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients	252
Population Mobility and Aging Accelerate the Transmission of Coronavirus Disease 2019 in the Deep South: A County-Level Longitudinal Analysis	237
Go V.I.R.A.L.: Social Media Engagement Strategies in Infectious Diseases	211
Association of Virus Variation and Vaccination Status With Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection	209
T-SPOT.TB Reactivity in Southern African Children With and Without in Utero Human Immunodeficiency Virus Exposure	199
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?	195
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?	160
Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021–August 2022	159
Reply to Darcis et al	152
Response to Rezahosseini and Barrella Harboe	151
Invasive Listeriosis in Southern Switzerland: A Local Problem That Is Actually Global	149
Corrigendum to: A New Specimen for Syphilis Diagnosis: Evidence by High Loads ofTreponema pallidumDNA in Saliva	134
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?	134
Case Investigation and Contact Tracing Efforts From Health Departments in the United States, November 2020 to December 2021	118
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 201	116
Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis	114

Validation of ISARIC 4C Mortality and Deterioration Scores in a Mixed Vaccination Status Cohort of Hospitalized Coronavirus Disease 2019 (COVID-19) Patients in Singapore	114
Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference	112
Does “Toxoplasma Abscess” Properly Describe Brain Lesions Caused by Toxoplasma gondii?	110
Susceptibility to Human Immunodeficiency Virus Type 1 Acquisition Linked to Malaria Exposure: A Case-Control Study	109
Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)	107
Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patie	107
Response to ‘Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome’	104
Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants	104
Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption	103
Daily Second-generation Integrase Strand Inhibitors and Short-course Tuberculosis Preventive Therapy: What More Do We Need to Know?	100
Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination	99
Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis	99
Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947–2019	98
Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study	98
Correction to: Prevalence of Ocular Complications in Candidemia: Defining the “Battlefield”	97
Empiric Antibiotics in Hospitalized Pneumonia: Discontinuation Is Better than De-escalation	95
Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa	95
Excess Invasive Meningococcal Disease Associated With Seasonal Influenza, South Africa, 2003–2018	95
Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection	94
Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort	93
Correction to: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Val	92
Pre-exposure Prophylaxis for Transgender People: A Systematic Review	90
Development of a Machine Learning Modeling Tool for Predicting HIV Incidence Using Public Health Data From a County in the Southern United States	89
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment	88
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial	87
Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021	86
Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for C. Difficile Infection	85
Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model	85
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study	82
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock	82
Considerations on the Associations Between Antiretroviral Regimen and Changes in Blood Pressure in the D2EFT Study	80
Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis	79
Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study	78
Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012–2013 to 2018–2019 Seasons, Quebec, Canada	76
Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation	76
Correction to: Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa	76
Clinical Presentation, Antimicrobial Resistance, and Treatment Outcomes of Aeromonas Human Infections: A 14-Year Retrospective Study and Comparative Genomics of 2 Isolates From Fatal Cases	75
Revisiting REVISIT: The Case for Ceftazidime/avibactam Plus Aztreonam	75
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States	74
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus	74
Point-of-care Ultrasound in Infectious Diseases: Current Insights and Future Perspectives	74
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Regist	74
Enhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With Human Immunodeficiency Virus Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial	73
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination	73
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial	73
Predictors of Mortality of Streptococcal Bacteremia and the Role of Infectious Diseases Consultation: A Retrospective Cohort Study	73
Are Contact Precautions “Essential” for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?	72
Circulation of Third-Generation Cephalosporin Resistant Salmonella Typhi in Mumbai, India	72
State-of-the-Art Review: Neurosyphilis	72
Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021	72

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70	71
CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?	71
Class-Specific Relationship Between Use of Immunosuppressants and Risk for Community-Acquired Clostridioides difficile Infection	71
How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection	71
Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave	70
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores	69
Chronic Aichi Virus Infection As a Cause of Long-Lasting Multiorgan Involvement in Patients With Primary Immune Deficiencies	68
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage	67
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial	67
Don’t Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C	66
Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making	66
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020–July 2021	66
Correction to: Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination	66
Comment on Parameswaran et al's “Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster Vaccine”	65
Prevention and Control of Coronavirus Disease 2019: Where Do We Go From Here?	65
Correction to: Coronavirus Disease 2019 Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study	65
Correction to: Higher Plasma Viremia in the Febrile Phase Is Associated With Adverse Dengue Outcomes Irrespective of Infecting Serotype or Host Immune Status: An Analysis of 5642 Vietnamese Cases	63
2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Staphylococcus aureus Bacteremia: Do We Already Know Enough?	63
Zinc and Coronavirus Disease 2019	63
Correction to: Transmission of Carbapenem-Resistant Enterobacterales in an Overcrowded Emergency Department: Controlling the Spread to the Hospital	62
In the Literature	62
Correction to: Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial	62
Evidence, Experience, Expertise, and the US Coronavirus Disease 2019 Public Health Response	61
Welcoming Discourse on the Approach for Gram-Negative Bacteremia and Candidemia in Cardiovascular Implantable Electronic Device Infections	61
Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation	60
Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory	60
Coronavirus Disease 2019: First Data From Africa	60
Increase in False-Positive Fourth-Generation Human Immunodeficiency Virus Tests in Patients With Coronavirus Disease 2019	60
The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic	60
Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Vaccination in Pregnancy	60
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19	60
Clinical Impact of Pleural Fluid Streptococcus pneumoniae Polymerase Chain Reaction Testing in Children With Complicated Pneumonia	59
Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population	59
Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023–2024	58
Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study	58
Advancing Access to Diagnostic Tools Essential for Universal Health Coverage and Antimicrobial Resistance Prevention: An Overview of Trials in Sub-Saharan Africa	58
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age	57
The Effects of Malaria in Pregnancy on Neurocognitive Development in Children at 1 and 6 Years of Age in Benin: A Prospective Mother–Child Cohort	57
Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak	56
High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia	56
Tuberculosis Treatment Outcomes in Brazil: Different Predictors for Each Type of Unsuccessful Outcome	56
High Time for Higher-Dose Rifampin	55
Treatment Completion and Sustained Virologic Response in the Context of Hepatitis C Virus Elimination: Time to Let Go of the Reins?	55
A 25-Year-Old Man With Fever, Diarrhea, and Shock	55
Clinical and Molecular Analyses of Recurrent Gram-Negative Bloodstream Infections	55
The Illusionary Correlation in Antibiotic Prescriptions: It May Exist but Requires Further Elucidation With Rigorous Methodology	55
Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset	55
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL	54
Serum Ammonia Screening and Donor Mollicutes Detection for Hyperammonemia Syndrome Post–Lung Transplantation: A Prospective Observational Study	54
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis	54
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccinat	54
The Promise and Peril of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibodies	54
Risk of Acute Myocardial Infarction Among Patients With Laboratory-Confirmed Invasive Pneumococcal Disease: A Self-Controlled Case Series Study	52
Recommendation to Take a Holistic View of the Dynamic Pathogenic Pneumococcal Environment	52
US Hospitalizations and 60-Day Readmission Rates Associated With Herpes Simplex Virus Encephalitis: Analysis of All Cause Readmissions and Encephalopathy Associated Readmissions	52
Patients Hospitalized With Coronavirus Disease 2019: A Diverse Population	52
Children and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission: A Step Closer to Better Understanding and Evidence-Based Interventions?	52
Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee	52
Side-by-side Comparative Study of the Immunogenicity of the Intramuscular and Intradermal Rabies Post-exposure Prophylaxis Regimens in a Cohort of Suspected Rabies Virus Exposed Individuals	52
Investigating Determinants of Pathogenicity of Carbapenemase–Producing Enterobacterales	51
CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study	51
Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model	51
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis	50
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South	50
Maternal and Perinatal Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy, Florida, 2020–2021: A Retrospective Cohort Study	50
Positive Effects of Cognitive-Behavioral Therapy Targeting Severe Fatigue Following COVID-19 Are Sustained Up to 1 Year After Treatment	50
Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre and Post-COVID (2019–2021)	49
Enteric Illness Outbreaks Reported Through the National Outbreak Reporting System—United States, 2009–2019	48
Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study	47
Screening for Chagas Disease Should Be Included in Entry-to-Care Testing for At-Risk People With Human Immunodeficiency Virus (HIV) Living in the United States	47
Remdesivir and Mortality in Patients With Coronavirus Disease 2019	47
Application of Pragmatic Criteria to Assessments of Frailty and Physical Function Among People With Human Immunodeficiency Virus (HIV)	46
Evaluation and Management of Diabetes-related Foot Infections	46
Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper	46
Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial	46
Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections	46
Total Antimicrobial Consumption in Doxycycline Postexposure Prophylaxis Cohorts and the Intensity of Screening for Bacterial Sexually Transmitted Infections	45
Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice	45
Human Immunodeficiency Virus/AIDS and Coronavirus Disease 2019: Shared Lessons From 2 Pandemics	45
Targeted Metagenomic Sequencing-based Approach Applied to 2146 Tissue and Body Fluid Samples in Routine Clinical Practice	45

A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes	44
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions	44
Estimating the Latent Period of Coronavirus Disease 2019 (COVID-19)	44
Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India	44
Maintaining the Utility of Coronavirus Disease 2019 Pandemic Severity Surveillance: Evaluation of Trends in Attributable Deaths and Development and Validation of a Measurement Tool	44
A Systematic Review of Human Challenge Trials, Designs, and Safety	44
Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection	44
Cost-Effective Treatment of Clostridiodes difficile Infection	43
Correction to: Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis	43
We Didn’t Start the Fire	43
In the Literature	43
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine	42
Cholesterol Contributes to Risk, Severity, and Machine Learning-Driven Diagnosis of Lyme Disease	42
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Compl	42
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study	42
Temporal Trends in Hepatitis C–Related Hospitalizations, United States, 2000–2019	42
Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the Uni	42
Integrating Scalable Genome Sequencing Into Microbiology Laboratories for Routine Antimicrobial Resistance Surveillance	41
Demise of the Milwaukee Protocol for Rabies	41
Beyond Burnout: The Power of Purpose, Partnership, and Serving Others	41
Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals	41
Duration of Replication-Competent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Shedding Among Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	40
Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum	40
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price	40
A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys	40
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review	40
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083	40
Risk of Psychiatric Disorders, Use of Psychiatric Hospitals, and Receipt of Psychiatric Medication in Patients With Brain Abscess in Denmark	40
Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial	40
Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)	39
Association Between Clostridium innocuum and Antibiotic-Associated Diarrhea in Adults and Children: A Cross-sectional Study and Comparative Genomics Analysis	39
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized	39
Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study	39
State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties	39
Acute Unilateral Vision Loss in a Young Woman	39
Correct Calculation of Confidence Interval for Proportion of Superior Comparisons Between Desirability of Outcome Ranking Scores	38
Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial	38
Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine	38
Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination	38
In the Literature	38
Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men	38
The Who, What, When, and Where of Inpatient Direct Oral Penicillin Challenge—Implications for Health Services Implementation	38
Associations Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants and Risk of Coronavirus Disease 2019 (COVID-19) Hospitalization Among Confirmed Cases in Washington State: A	38
Prosthetic Joint Infections and Rifampin	38
The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort	38
An Ensemble Framework for Projecting the Impact of Lymphatic Filariasis Interventions Across Sub-Saharan Africa at a Fine Spatial Scale	37
Japanese Encephalitis Emergence in Australia: The Potential Population at Risk	37
Applying Desirability of Outcome Ranking End Points	37
Duration of Effective Tuberculosis Treatment, Not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for De-isolation in Community Settings	37
Declined Mortality Due to Seasonal Influenza in Japan During the Coronavirus Disease 2019 Pandemic	37
BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of Coronavirus Disease 2019 Patients	37
Cost-effectiveness of Check It: A Novel Community-Based Chlamydia Screening and Expedited Treatment Program for Young Black Men	37
Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis?	37
HIV, HIV-Specific Factors, and Myocardial Disease in Women	37
Pleural Empyema: Etiology and Pathogenesis	37
Vaccine-Preventable Disease Outbreaks Among Healthcare Workers: A Scoping Review	36
Questions About the 2023 Infective Endocarditis Updated Criteria	36
Lung and Brain Abscesses in an Upper Extremity Allotransplantation Recipient	36
Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study	36
Reply to Chu et al	36
Put the Fluoroquinolone Down and No One Gets Hurt	36
Impact of Clinician Feedback Reports on Antibiotic Use in Children Hospitalized With Community-acquired Pneumonia	36
Collaborative Strategies for Antimicrobial Stewardship Programs: Navigating Financial and Regulatory Landscapes	36
Fever and Extensive Blistering in a Patient With Atopic Dermatitis	36
Cause of Death in Neonates With Neurological Insults in the Neonatal Intensive Care Unit: Insights From A MITS Pilot Study	36
Management of Diarrhea in Young Children in Sub-Saharan Africa: Adherence to World Health Organization Recommendations During the Global Enteric Multisite Study (2007–2011) and the Vaccine Impact of D	36
Low CD4+ Cell Counts Linked to Mortality Rate After Sustained Virological Response: Evaluating Interaction With Liver Stiffness Versus the Fibrosis-4 Score	36
Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Di	35
Environmental Testing of Surfaces in the Room of a Patient With Mpox	35
Reference Susceptibility Testing and Genomic Surveillance ofClostridioides difficile, United States, 2012–17	35
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections	35
Utilizing Human Immunodeficiency Virus (HIV) Proviral DNA to Assess for the Presence of HIV Drug Resistance	35
Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia	35
Antibiotic Indications and Appropriateness in the Pediatric Intensive Care Unit: A 10-Center Point Prevalence Study	35
Current Epidemiology and Clinical Features of Cryptococcus Infection in Patients Without Human Immunodeficiency Virus: A Multicenter Study in 46 Hospitals in Australia and New Zealand	35
Human Immunodeficiency Virus Type 2 (HIV-2) EU—Supporting Standardized HIV-2 Drug Resistance Interpretation: An Update	35
Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults	35
Enterococcus Intestinal Domination Is Associated With Increased Mortality in the Acute Leukemia Chemotherapy Population	35
Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020–2021: A Case-Ascertained, Prospecti	35
Prenatal Influenza Vaccination or Influenza Infection and Autism Spectrum Disorder in Offspring	34
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients	34
The Dynamic Impact of Community Social Vulnerability on COVID-19 Outcomes: A Census Tract-level Analysis of Fulton County, Georgia	34
The Performance of Computer-Aided Detection Digital Chest X-ray Reading Technologies for Triage of Active Tuberculosis Among Persons With a History of Previous Tuberculosis	34
High Cytomegalovirus Viral Load Is Associated With 182-Day All-Cause Mortality in Hospitalized People With Human Immunodeficiency Virus	34
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019	34
Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study	34
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis	34
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses	34
Sex Differences in Long-term Outcomes After Group B Streptococcal Infections During Infancy in Denmark and the Netherlands: National Cohort Studies of Neurodevelopmental Impairments and Mortality	34
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries	34
Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadriva	34
National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States	33
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)	33
Vaccines, Variants, and Vigilance: Strengthening the Coronavirus Disease 2019 (COVID-19) Public Health Response Through Partnerships and Collaborations	33
In the Literature	33